Table 2. Clinicopathologic factors and their effect on overall survival and relapse-free survival by univariate and multivariate Cox proportional hazards regression analysis.

Characteristics	N	OS		RFS
		HR (95% CI)	p	HR (95% CI)	p
Univariate analysis
Age, yr, ≥30 (vs. <30)	10/35	2.507 (0.886–7.093)	0.083	2.810 (1.039–7.598)	0.042
Sex, male (vs. female)	25/35	1.684 (0.470–6.028)	0.423	2.025 (0.567–7.237)	0.278
Tumor size, cm, >8 (vs. ≤8)	18/35	3.591 (1.126–11.459)	0.031	3.318 (1.131–9.737)	0.029
Stage, I	11/35	1	0.024	1	0.027
II	19/35	8.090 (1.041–62.838)	0.046	8.933 (1.157–68.974)	0.036
III–IV	5/35	23.521 (2.382–232.242)	0.007	23.559 (2.338–237.356)	0.007
Distant metastasis, presence (vs. absence)	5/35	4.551 (1.237–16.748)	0.023	4.078 (1.097–15.162)	0.036
Histological grade, high (vs. low)	24/35	9.335 (1.223–71.232)	0.031	10.022 (1.317–76.243)	0.026
DBC1, positive (vs. negative)	17/35	8.639 (1.940–38.469)	0.005	6.657 (1.875–23.629)	0.003
AR, positive (vs. negative)	17/35	5.551 (1.551–19.864)	0.008	4.201 (1.336–13.216)	0.014
Multivariate analysis Model 1*
Age, yr, ≥30 (vs. <30)				2.652 (0.971–7.239)	0.057
DBC1, positive (vs. negative)		8.639 (1.940–38.469)	0.005	6.555 (1.825–23.549)	0.004
Multivariate analysis Model 2**
Age, yr, ≥30 (vs. <30)				2.864 (1.017–8.066)	0.046
Tumor size, cm, >8 (vs. ≤8)		3.891 (1.169–12.950)	0.027	3.777 (1.205–11.846)	0.023
AR, positive (vs. negative)		5.892 (1.616–21.480)	0.007	3.975 (1.194–13.238)	0.025

OS, overall survival; RFS, relapse-free survival; HR, hazard ratio; 95% CI, 95% confidence interval; DBC1, deleted in breast cancer 1; AR, androgen receptor.

^*Variables considered in the multivariate analysis Model 1 were the age, tumor size, tumor stage, distant metastasis, histologic grade, DBC1 expression, and AR expression.

^**Variables considered in the multivariate analysis Model 2 were the age, tumor size, tumor stage, distant metastasis, histologic grade, and AR expression.